TITLE

Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma

AUTHOR(S)
Lacy, Martha Q.; Gertz, Morie A.; Dispenzieri, Angela; Hayman, Suzanne R.; Geyer, Susan; Kabat, Brian; Zeldenrust, Steven R.; Kumar, Shaji; Greipp, Philip R.; Fonseca, Rafael; Lust, John A.; Russell, Stephen J.; Kyle, Robert A.; Witzig, Thomas E.; Bergsagel, P. Leif; Stewart, A. Keith; Rajkumar, S. Vincent
PUB. DATE
October 2007
SOURCE
Mayo Clinic Proceedings;Oct2007, Vol. 82 Issue 10, p1179
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To determine the long-term effects of a combined regimen of lenalldomide and dexamethasone (Rev-Dex) on time to progression, progression-free survival, and overall survival (OS) in patients with multiple myeloma. PATIENTS AND METHODS: From March 2004 through October 2004, 34 patients were registered for the study. They were treated with 25 mg/d of lenalidomide on days 1 through 21 of a 28-day cycle and 40 mg/d of dexamethasone on days 1 through 4, 9 through 12, and 17 through 20 of each cycle. After 4 cycles of therapy, patients were allowed to discontinue treatment to pursue autologous stem cell transplant (SCT). Treatment beyond 4 cycles was permitted at the physician's discretion. RESULTS: Thirteen patients proceeded to SCT after initial therapy and were censored at that time point for purposes of calculation of response. Thirty-one patients achieved an objective response, defined as a partial response or better (91%; 95% confidence interval, 79%-98%), with a complete response plus very good partial response rate of 56%. The complete response plus very good partial response among the 21 patients who received Rev-Dex without SCT was 67%. The 2-year progression-free survival rates for patients proceeding to SCT and patients remaining on Rev-Dex were 83% and 59%, respectively; the OS rates were 92% and 90% at 2 years and 92% and 85% at 3 years, respectively. The 3-year OS rate for the whole cohort was 88%. CONCLUSION: The Rev-Dex regimen is highly active in the treatment of newly diagnosed multiple myeloma. Responses are durable with a low progression rate at 2 years. Randomized trials that incorporate quality-of-life measures are needed to determine if this and other combination regimens are better used early in therapy or should be reserved for later interventions.
ACCESSION #
27176885

 

Related Articles

  • Total therapy-based treatment for multiple myeloma—a single center experience. Magen-Nativ, Hila; Ram, Ron; Yeshurun, Moshe; Gafter-Gvili, Anat; Raanani, Pia; Shpilberg, Ofer // Annals of Hematology;Jan2010, Vol. 89 Issue 1, p53 

    Incorporation of novel biological agents has become the cornerstone of treatment in multiple myeloma. For the last 4 years we have adopted the more intensified approach, previously published as total therapy 3 by the Arkansas group and used it with local modifications. This study aims to...

  • New developments in conditioning regimens before auto-SCT in multiple myeloma. Moreau, P.; Attal, M.; Harousseau, J. L. // Bone Marrow Transplantation;Jul2011, Vol. 46 Issue 7, p911 

    The current standard conditioning regimen before auto-SCT in patients with multiple myeloma is melphalan 200 mg/m2. Several attempts have recently been made to improve this aspect of the high-dose therapy procedure. The scope of this review article is to summarize current knowledge on...

  • Combination of Bortezomib and Thalidomide Used as Maintenance Improves Overall Survival in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma.  // Journal of Hematology Oncology Pharmacy;Mar2014, Vol. 4 Issue 1, p3 

    Background: Patients with multiple myeloma (MM) who are not fit to undergo stem-cell transplantation typically receive melphalan plus prednisone in combination with either thalidomide or bortezomib. Recent studies are exploring the clinical benefit of the 4-drug induction regimen of bortezomib,...

  • Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trials. Minjie Gao; Guang Yang; Ying Han; Yuanyuan Kong; Huiqun Wu; Yi Tao; Fenghuang Zhan; Jumei Shi; Xiaosong Wu // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 8, p12202 

    The efficacy and safety of single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation (ASCT) in patients with multiple myeloma (MM) has been in question. To address the issue, we conducted a meta-analysis of two...

  • The Real World Effectiveness of Hematopoietic Transplant Among Elderly Individuals With Multiple Myeloma. Winn, Aaron N.; Shah, Gunjan L.; Cohen, Joshua T.; Pei-Jung Lin; Parsons, Susan K. // JNCI: Journal of the National Cancer Institute;8/12/2015, Vol. 107 Issue 8, p1 

    Background: Hematopoietic stem cell transplant (HSCT) is the preferred treatment for young patients with multiple myeloma (MM), but for older adults there is limited evidence on its effectiveness from clinical trials. Methods: We used the Surveillance, Epidemiology, and End Results...

  • Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Olin, R. L.; Vogl, D. T.; Porter, D. L.; Luger, S. M.; Schuster, S. J.; Tsai, D. E.; Siegel, D. L.; Cook, R. J.; Mangan, P. A.; Cunningham, K.; Stadtmauer, E. A. // Bone Marrow Transplantation;Mar2009, Vol. 43 Issue 5, p417 

    Therapeutic options for patients with multiple myeloma whose disease has relapsed after a prior auto-SCT include novel biologic therapies, traditional chemotherapy or a second transplant, with no clear standard of care. Few published studies address the safety and efficacy of a second auto-SCT...

  • Autologous transplantation for multiple myeloma. Harousseau, J. -L. // Annals of Oncology;Sep2008 Supplement 7, Vol. 19, p128 

    The article presents a study on the use of autologous stem cell transplantation (ASCT) as frontline therapy of multiple myeloma (MM) in younger patients. It states that ASCT is beneficial when all patients are randomized at diagnosis than when randomization is performed after induction...

  • Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative. Gertz, Morie A.; Ansell, Stephen M.; Dingli, David; Dispenzieri, Angela; Buadi, Francis K.; Elliott, Michelle A.; Gastineau, Dennis A.; Hayman, Suzanne R.; Hogan, William J.; Inwards, David J.; Johnston, Patrick B.; Kumar, Shaji; Lacy, Martha Q.; Leung, Nelson; Micallef, Ivana N. M.; Porrata, Luis F.; Schafer, Barbara A.; Wolf, Robert C.; Litzow, Mark R. // Mayo Clinic Proceedings;Oct2008, Vol. 83 Issue 10, p1131 

    We report on the feasibility of outpatient transplant in 716 patients undergoing autologous stem cell transplant for multiple myeloma at Mayo Clinic's site in Rochester, MN, from January 1, 2000, through October 31, 2007. We also report on the development and effect of a multidisciplinary...

  • Millennium: pushing for broader use of Velcade.  // PharmaWatch: Biotechnology;Oct2007, Vol. 6 Issue 10, p9 

    The article reports on the plan of Millennium Pharmaceuticals to initiate a Phase II trial that evaluates a Velcade-based for the treatment of multiple myeloma. This randomized trial tends to evaluate a combination of injectable Velcade including Revlimid and dexamethasone. Moreover, an ongoing...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics